MedPath

AV-101

Generic Name
AV-101
Drug Type
Small Molecule
Chemical Formula
C10H11ClN2O3
CAS Number
153152-32-0
Unique Ingredient Identifier
77XLH9L40B
Background

AV-101 has been used in trials studying the treatment of Neuropathic Pain.

Clinical Trials
Related News

Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial - Follow Up Long Term Extension (IMPAHCT-FUL)

Phase 3
Terminated
Conditions
Pulmonary Arterial Hypertension
Interventions
First Posted Date
2022-09-28
Last Posted Date
2024-10-10
Lead Sponsor
Aerovate Therapeutics
Target Recruit Count
186
Registration Number
NCT05557942
Locations
🇺🇸

UCLA/David Geffen School of Medicine-Pulmonary and Criticial Care, Los Angeles, California, United States

🇺🇸

Ohio State University, Columbus, Ohio, United States

🇺🇸

Indiana University Health, Indianapolis, Indiana, United States

and more 69 locations

AV-101 Alone and in Combination With Probenecid in Healthy Subjects

Phase 1
Conditions
Drug Drug Interaction
Interventions
First Posted Date
2022-03-15
Last Posted Date
2022-03-15
Lead Sponsor
VistaGen Therapeutics, Inc.
Target Recruit Count
24
Registration Number
NCT05280054
Locations
🇺🇸

Parexel Early Phase Clinical Unit, Glendale, California, United States

A Study of AV-101 (Dry Powder Inhaled Imatinib) in Patients With Pulmonary Arterial Hypertension (PAH)

Phase 2
Terminated
Conditions
Pulmonary Arterial Hypertension
Interventions
Drug: Placebo
First Posted Date
2021-09-05
Last Posted Date
2024-08-23
Lead Sponsor
Aerovate Therapeutics
Target Recruit Count
202
Registration Number
NCT05036135
Locations
🇺🇸

Tufts Medical Center, Inc., Boston, Massachusetts, United States

🇬🇷

AHEPA General Hospital of Thessaloniki, Thessaloníki, Greece

🇺🇸

University of Minnesota, Minneapolis, Minnesota, United States

and more 125 locations

AV-101 (L-4-chlorokynurenine) in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesia

Phase 2
Conditions
L-Dopa Causing Adverse Effects in Therapeutic Use
Dyskinesia, Medication-Induced
Parkinson Disease
Interventions
Drug: Placebo
First Posted Date
2019-11-01
Last Posted Date
2021-05-26
Lead Sponsor
VistaGen Therapeutics, Inc.
Target Recruit Count
20
Registration Number
NCT04147949

Electrophysiological Biomarkers of AV-101

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Placebo
First Posted Date
2018-07-11
Last Posted Date
2022-02-17
Lead Sponsor
Marijn Lijffijt, PhD
Target Recruit Count
18
Registration Number
NCT03583554
Locations
🇺🇸

Michael E. DeBakey VA Medical Center, Houston, Texas, United States

AV-101 as Adjunct Antidepressant Therapy in Patients With Major Depression

Phase 2
Completed
Conditions
Major Depressive Disorder
Interventions
Drug: Placebo
First Posted Date
2017-03-13
Last Posted Date
2019-10-09
Lead Sponsor
VistaGen Therapeutics, Inc.
Target Recruit Count
180
Registration Number
NCT03078322
Locations
🇺🇸

VistaGen Investigational Site, Bellevue, Washington, United States

Safety, Tolerability and Pharmacokinetics of Multiple Doses of AV-101 in Healthy Volunteers

Phase 1
Completed
Conditions
Neuropathic Pain
Interventions
Drug: Placebo
First Posted Date
2011-12-01
Last Posted Date
2012-12-20
Lead Sponsor
VistaGen Therapeutics, Inc.
Target Recruit Count
50
Registration Number
NCT01483846
Locations
🇺🇸

UCSD Medical Center, San Diego, California, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy